239 related articles for article (PubMed ID: 9486962)
1. Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation.
Sylvester AM; Chen D; Krasinski K; Andrés V
J Clin Invest; 1998 Mar; 101(5):940-8. PubMed ID: 9486962
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation.
Goukassian D; Sanz-González SM; Pérez-Roger I; Font de Mora J; Ureña J; Andrés V
Br J Pharmacol; 2001 Apr; 132(7):1597-605. PubMed ID: 11264255
[TBL] [Abstract][Full Text] [Related]
3. Roles of E2F1 in mesangial cell proliferation in vitro.
Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F
Kidney Int; 1999 Dec; 56(6):2085-95. PubMed ID: 10594784
[TBL] [Abstract][Full Text] [Related]
4. Age-associated changes in basal c-fos transcription factor binding activity in rat hearts.
Tsou H; Azhar G; Lu XG; Kovacs S; Peacocke M; Wei JY
Exp Cell Res; 1996 Dec; 229(2):432-7. PubMed ID: 8986626
[TBL] [Abstract][Full Text] [Related]
5. Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I.
Huang Y; Ohtani K; Iwanaga R; Matsumura Y; Nakamura M
Oncogene; 2001 Mar; 20(9):1094-102. PubMed ID: 11314046
[TBL] [Abstract][Full Text] [Related]
6. A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and anti-repression by E2F.
Liu N; Lucibello FC; Engeland K; Müller R
Oncogene; 1998 Jun; 16(23):2957-63. PubMed ID: 9662327
[TBL] [Abstract][Full Text] [Related]
7. K-ras modulates the cell cycle via both positive and negative regulatory pathways.
Fan J; Bertino JR
Oncogene; 1997 May; 14(21):2595-607. PubMed ID: 9191059
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent increase in c-fos activity and cyclin A expression in vascular smooth muscle cells. A potential link between aging, smooth muscle cell proliferation and atherosclerosis.
Rivard A; Principe N; Andrés V
Cardiovasc Res; 2000 Mar; 45(4):1026-34. PubMed ID: 10728429
[TBL] [Abstract][Full Text] [Related]
9. Activating transcription factor 2 is necessary for maximal activity and serum induction of the cyclin A promoter in chondrocytes.
Beier F; Taylor AC; LuValle P
J Biol Chem; 2000 Apr; 275(17):12948-53. PubMed ID: 10777595
[TBL] [Abstract][Full Text] [Related]
10. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity.
Johnson DG
Oncogene; 1995 Nov; 11(9):1685-92. PubMed ID: 7478595
[TBL] [Abstract][Full Text] [Related]
11. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation.
Kiess M; Gill RM; Hamel PA
Cell Growth Differ; 1995 Oct; 6(10):1287-98. PubMed ID: 8845306
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F.
Kim MJ; Park KG; Lee KM; Kim HS; Kim SY; Kim CS; Lee SL; Chang YC; Park JY; Lee KU; Lee IK
Hypertension; 2005 Apr; 45(4):552-6. PubMed ID: 15723965
[TBL] [Abstract][Full Text] [Related]
13. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of specific E2F complexes by the v-mos oncogene.
Afshari CA; Rhodes N; Paules RS; Mudryj M
Oncogene; 1997 Jun; 14(25):3029-38. PubMed ID: 9223666
[TBL] [Abstract][Full Text] [Related]
15. Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression.
Sanz-González SM; Castro C; Pérez P; Andrés V
Biochem Biophys Res Commun; 2004 May; 317(4):972-9. PubMed ID: 15094364
[TBL] [Abstract][Full Text] [Related]
16. Growth suppression of human coronary vascular smooth muscle cells by gene transfer of the transcription factor E2F-1.
Shelat HS; Liu TJ; Hickman-Bick DL; Barnhart MK; Vida T; Dillard PM; Willerson JT; Zoldhelyi P
Circulation; 2001 Jan; 103(3):407-14. PubMed ID: 11157693
[TBL] [Abstract][Full Text] [Related]
17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
18. Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells.
Sala A; Nicolaides NC; Engelhard A; Bellon T; Lawe DC; Arnold A; Graña X; Giordano A; Calabretta B
Cancer Res; 1994 Mar; 54(6):1402-6. PubMed ID: 8137237
[TBL] [Abstract][Full Text] [Related]
19. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P
Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707
[TBL] [Abstract][Full Text] [Related]
20. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter.
Rotheneder H; Geymayer S; Haidweger E
J Mol Biol; 1999 Nov; 293(5):1005-15. PubMed ID: 10547281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
